Although different mechanisms for the maintenance of reservoirs of latent HIV-infection have been advanced, the spectrum of emerging trial anti-HIV latency 'pro-drugs' is largely limited to those agents functioning via the awakening of resting host (CD4+ memory) cells; a strategy primarily meant to exorcise the latent provirus [5,6]. Here, CD4 is linked to HIV infectious disease.